This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics
by Zacks Equity Research
AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.
Impax Laboratories and Amneal Pharmaceuticals Agree to Merge
by Zacks Equity Research
Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
by Zacks Equity Research
Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.
Immune Design's Sarcoma Candidate to Enter Phase III in 2018
by Zacks Equity Research
Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.
Bristol-Myers Gets Priority Review for Opdivo Label Expansion
by Zacks Equity Research
Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.
Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Why Should You Invest in Novo Nordisk (NVO) Stock Right Now
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.
4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3
by Zacks Equity Research
The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.
Johnson & Johnson Files sNDA for Label Expansion of Invokana
by Zacks Equity Research
Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.
Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.
Orexigen's (OREX) Contrave Sales Improving on Promotions
by Zacks Equity Research
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day
by Arpita Dutt
With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.
Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View
by Zacks Equity Research
Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.
The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk
Top Analyst Reports for Apple, Pfizer & Carnival
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Pfizer (PFE) and Carnival (CCL).
Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?
by Zacks Equity Research
Teva Pharmaceutical (TEVA) announced the appointment of H. Lundbeck's Kare Schultz as President and Chief Executive Officer (CEO).
Novo Nordisk's Tresiba Gets Canadian Nod
by Zacks Equity Research
Novo Nordisk's (NVO) Tresiba is approved by Health Canada for the once-daily treatment of adults with diabetes mellitus to improve glycemic control.
Novo Nordisk's Victoza Gets FDA Nod for Label Expansion
by Zacks Equity Research
Novo Nordisk's (NVO) Victoza receives FDA nod for its label expansion to include cardiovascular events in adult patients with type II diabetes. Shares up.
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk
Novo Nordisk's Semaglutide Shows Remarkable Results in Study
by Zacks Equity Research
Novo Nordisk (NVO) pipeline candidate shows superior glucose control and weight loss in study in diabetes patients compared with Eli Lilly and Co's Trulicity (dulaglutide).
Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss
by Zacks Equity Research
Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.
Why Earnings Season Could Be Great for Novo Nordisk (NVO)
by Zacks Equity Research
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Allergan (AGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan plc's (AGN) Q2 sales are likely to be driven by new as well as established products and international growth, earnings will likely be driven by sales growth and cost control.
Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?
by Zacks Equity Research
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.